Subsequent observational retrospective series of critically ill Chinese COVID-19 patients treated with tocilizumab also reported a decrease in CRP levels, mechanical ventilation risk and mortality rate (Xu et al., 2020). This evidence concerns the gene CRP and COVID-19.